# A Study of GDC-0810 Versus Fulvestrant in Postmenopausal Women With Advanced or Metastatic Breast Cancer Resistant to Aromatase Inhibitor (AI) Therapy

> **NCT02569801** · PHASE2 · TERMINATED · sponsor: **Genentech, Inc.** · enrollment: 71 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Fulvestrant
- **DRUG:** GDC-0810

## Key facts

- **NCT ID:** NCT02569801
- **Lead sponsor:** Genentech, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-12-04
- **Primary completion:** 2020-02-28
- **Final completion:** 2020-02-28
- **Target enrollment:** 71 (ACTUAL)
- **Why stopped:** The Sponsor decided to halt the development of GDC-0810, but not due to any safety concerns.
- **Last updated:** 2021-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02569801

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02569801, "A Study of GDC-0810 Versus Fulvestrant in Postmenopausal Women With Advanced or Metastatic Breast Cancer Resistant to Aromatase Inhibitor (AI) Therapy". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT02569801. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*